imprint:
Springer Science and Business Media LLC, 2020
Published in:BMC Ophthalmology
Language:
English
DOI:
10.1186/s12886-020-01723-3
ISSN:
1471-2415
Origination:
Footnote:
Description:
<jats:title>Abstract</jats:title><jats:sec>
<jats:title>Background</jats:title>
<jats:p>To evaluate the influence of Selective Laser Trabeculoplasty (SLT) on iStent inject® outcomes in open-angle glaucoma (OAG).</jats:p>
</jats:sec><jats:sec>
<jats:title>Methods</jats:title>
<jats:p>In this retrospective comparative cohort outcome study, 66 patients who were treated with two iStent inject® devices were included. Patients were divided into two subgroups consisting of patients without SLT treatment prior to surgery and patients who had been treated previously with 360° SLT but without sufficient response. Outcome measures included intraocular pressure (IOP) and number of antiglaucoma medications after 6 weeks with three, six, 12, and 24 month follow-ups.</jats:p>
</jats:sec><jats:sec>
<jats:title>Results</jats:title>
<jats:p>Mean preoperative IOP decreased from 20.4 ± 5.3 mmHg to 14.8 ± 3.0 mmHg for patients without SLT treatment prior to surgery (<jats:italic>p</jats:italic> = 0.001) and from 19.2 ± 4.5 mmHg to 14.0 ± 1.6 mmHg for patients with insufficient response to 360° SLT treatment (<jats:italic>p</jats:italic> = 0.027) at 12 months after iStent inject® implantation. No significant difference was found between the two groups (<jats:italic>p</jats:italic> > 0.05). The number of antiglaucoma medications did not change in both groups (<jats:italic>p</jats:italic> > 0.05) and showed no significant difference between the two groups (<jats:italic>p</jats:italic> > 0.05).</jats:p>
</jats:sec><jats:sec>
<jats:title>Conclusion</jats:title>
<jats:p>Prior SLT treatment seems to have no negative influence on the IOP lowering-effect of iStent inject® implantation in patients with OAG. It is therefore an appropriate incremental procedure with no exclusion criterion for an iStent inject® implantation.</jats:p>
</jats:sec>